Literature DB >> 25974108

Bilateral Choroidopathy and Serous Retinal Detachments During Ipilimumab Treatment for Cutaneous Melanoma.

Dimosthenis Mantopoulos1, Kari L Kendra2, Alan D Letson1, Colleen M Cebulla1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25974108      PMCID： PMC4537365          DOI： 10.1001/jamaophthalmol.2015.1128

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN： 2168-6165            Impact factor:   7.389


× No keyword cloud information.
  6 in total

1.  Melanoma-associated retinopathy treated with ipilimumab therapy.

Authors:  A Audemard; S de Raucourt; S Miocque; F Comoz; J M Giraud; B Dreno; B Bienvenu; M-J Rogerie; A Dompmartin
Journal:  Dermatology       Date:  2013-09-14       Impact factor: 5.366

2.  Bilateral drug (ipilimumab)-induced vitritis, choroiditis, and serous retinal detachments suggestive of vogt-koyanagi-harada syndrome.

Authors:  Ryan K Wong; Jimmy K Lee; John J Huang
Journal:  Retin Cases Brief Rep       Date:  2012

3.  Multifocal bilateral choroidal neovascularization in a patient on ipilimumab for metastatic melanoma.

Authors:  Bobeck S Modjtahedi; Howard Maibach; Susanna Park
Journal:  Cutan Ocul Toxicol       Date:  2013-05-28       Impact factor: 1.820

4.  Multifocal radiculoneuropathy during ipilimumab treatment of melanoma.

Authors:  Georgios Manousakis; James Koch; R Brian Sommerville; Ahmed El-Dokla; Matthew B Harms; Muhammad T Al-Lozi; Robert E Schmidt; Alan Pestronk
Journal:  Muscle Nerve       Date:  2013-07-27       Impact factor: 3.217

5.  Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis).

Authors:  Ilknur Tugal-Tutkun; Carl P Herbort; Moncef Khairallah
Journal:  Int Ophthalmol       Date:  2008-09-16       Impact factor: 2.031

6.  The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.

Authors:  Caroline J Voskens; Simone M Goldinger; Carmen Loquai; Caroline Robert; Katharina C Kaehler; Carola Berking; Tanja Bergmann; Clemens L Bockmeyer; Thomas Eigentler; Michael Fluck; Claus Garbe; Ralf Gutzmer; Stephan Grabbe; Axel Hauschild; Rüdiger Hein; Gheorghe Hundorfean; Armin Justich; Ullrich Keller; Christina Klein; Christine Mateus; Peter Mohr; Sylvie Paetzold; Imke Satzger; Dirk Schadendorf; Marc Schlaeppi; Gerold Schuler; Beatrice Schuler-Thurner; Uwe Trefzer; Jens Ulrich; Julia Vaubel; Roger von Moos; Patrik Weder; Tabea Wilhelm; Daniela Göppner; Reinhard Dummer; Lucie M Heinzerling
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240
  6 in total
  19 in total

1.  Bilateral uveitis associated with nivolumab therapy for metastatic melanoma: a case report.

Authors:  Daniel Russell Richardson; Brian Ellis; Inderjit Mehmi; Monique Leys
Journal:  Int J Ophthalmol       Date:  2017-07-18       Impact factor: 1.779

2.  Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies.

Authors:  Carl W Noble; Sapna S Gangaputra; Ian A Thompson; Amy Yuan; Andrea B Apolo; Jung-Min Lee; George N Papaliodis; Shilpa Kodati; Rachel Bishop; M Teresa Magone; Lucia Sobrin; H Nida Sen
Journal:  Ocul Immunol Inflamm       Date:  2019-04-23       Impact factor: 3.070

Review 3.  Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management.

Authors:  Yu-Wen Zhou; Qian Xu; Yan Wang; Ruo-Lan Xia; Ji-Yan Liu; Xue-Lei Ma
Journal:  Int J Ophthalmol       Date:  2022-04-18       Impact factor: 1.779

Review 4.  Neuro-ophthalmic side effects of molecularly targeted cancer drugs.

Authors:  M T Bhatti; A K S Salama
Journal:  Eye (Lond)       Date:  2017-10-20       Impact factor: 3.775

Review 5.  Ocular Toxicity of Targeted Anticancer Agents.

Authors:  Blake H Fortes; Prashant D Tailor; Lauren A Dalvin
Journal:  Drugs       Date:  2021-03-31       Impact factor: 9.546

6.  Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma.

Authors:  Laura Hahn; Kathryn L Pepple
Journal:  J Ophthalmic Inflamm Infect       Date:  2016-05-10

7.  Acute visual loss after ipilimumab treatment for metastatic melanoma.

Authors:  Melissa A Wilson; Kelly Guld; Steven Galetta; Ryan D Walsh; Julia Kharlip; Madhura Tamhankar; Suzanne McGettigan; Lynn M Schuchter; Leslie A Fecher
Journal:  J Immunother Cancer       Date:  2016-10-18       Impact factor: 13.751

8.  Progressive choroidal thinning (leptochoroid) and fundus depigmentation associated with checkpoint inhibitors.

Authors:  Julia Canestraro; Korey A Jaben; Jedd D Wolchok; David H Abramson; Jasmine H Francis
Journal:  Am J Ophthalmol Case Rep       Date:  2020-06-26

9.  Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors.

Authors:  Suthee Rapisuwon; Benjamin Izar; Cory Batenchuk; Alexandre Avila; Shaolin Mei; Peter Sorger; Jerry M Parks; Sarah J Cooper; David Wagner; Jay C Zeck; Aline J Charabaty; Michael B Atkins
Journal:  J Immunother Cancer       Date:  2019-03-04       Impact factor: 13.751

10.  Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy.

Authors:  Xiaowei Liu; Zheng Wang; Chan Zhao; Hanping Wang; Xiaoxiao Guo; Jiaxin Zhou; Lian Duan; Xiaoyan Si; Li Zhang; Yue Li; Mengzhao Wang; Meifen Zhang; Li Zhang
Journal:  Thorac Cancer       Date:  2020-02-04       Impact factor: 3.500
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.